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ABSTRACT
How countries, particularly low- and middle-income economies, should pay the coronavirus disease 2019 
(COVID-19) vaccine is an important and understudied issue. We undertook an online survey to measure 
the willingness-to-pay (WTP) for a COVID-19 vaccine and its determinants in Indonesia. The WTP was 
assessed using a simple dichotomous contingent valuation approach and a linear regression model was 
used to assess its associated determinants. There were 1,359 respondents who completed the survey. In 
total, 78.3% (1,065) were willing to pay for the COVID-19 vaccine with a mean and median WTP of US$ 
57.20 (95%CI: US$ 54.56, US$ 59.85) and US$ 30.94 (95%CI: US$ 30.94, US$ 30.94), respectively. Being 
a health-care worker, having a high income, and having high perceived risk were associated with higher 
WTP. These findings suggest that the WTP for a COVID-19 vaccine is relatively high in Indonesia. This WTP 
information can be used to construct a payment model for a COVID-19 vaccine in the country. 
Nevertheless, to attain higher vaccine coverage, it may be necessary to partially subsidize the vaccine 
for those who are less wealthy and to design health promotion materials to increase the perceived risk for 
COVID-19 in the country.
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The current global pandemic of coronavirus disease 2019 
(COVID-19) is a major international threat.1 More than 
10 million confirmed cases have been reported with more 
than a half million deaths globally.2 In Indonesia, more than 
100 thousand confirmed cases and 5,000 deaths have been 
reported as of August 13, 2020.2 As a response to the pandemic, 
over 500 clinical trials to assess the efficacy and safety of 
candidate interventions have been registered in international 
clinical trial registry platforms.3 Apart from effective treat-
ments, the development of vaccines is a priority to mitigate 
the pandemic, according to the WHO Research and 
Development Blueprint.4 Currently, more than 100 vaccine 
candidates are in the development pipeline.5 The first vaccine 
candidate entered a Phase 1 clinical trial on March 16, 2020,6 
and as of April 9, 2020, five candidates had entered Phase 1 
clinical trials.5 On June 13, results of the first phase 1 clinical 
trial of a COVID-19 vaccine candidate, the Ad5 vectored 
vaccine, were released and found that the vaccine is tolerable 
and the humoral responses against SARS-CoV-2 peaked at d 28 
post-vaccination.7 Given this accelerated speed of vaccine 
development, a COVID-19 vaccine might be available in the 
near future.8
Even with a safe and efficacious COVID-19 vaccine, it is not 
clear that individuals will accept and purchase the vaccine. 
Therefore, it is important to evaluate acceptance and willing-
ness-to-pay (WTP) for a vaccine. Assessment of WTP, defined 
as the maximum amount of money that individuals would be 
willing to pay for a vaccine, not only determines the potential 
market but also obtains information to be incorporated in 
formulating the best payment strategy for a new vaccine. 
WTP is influenced by many factors including sociodemo-
graphic characteristics as well as preexisting attitudes and 
beliefs of individuals.9–13 These characteristics do not necessa-
rily have consistent relationships with WTP across 
communities.9 Therefore, identification of determinants asso-
ciated with WTP for COVID-19 is also key for the government 
and other organizations to develop a well-designed interven-
tion program for use in key populations. This is crucial in 
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particular to achieve high COVID-19 vaccine coverage espe-
cially in low- and middle-income countries (LMICs) which 
may not have the fiscal capacity to fully subsidize the vaccine 
for every resident.
Studies assessing acceptance and WTP of a COVID-19 
vaccine are limited. A previous study has assessed preferences 
for COVID-19 vaccination in China among health-care work-
ers but this study did not assess the WTP.14 A study in 
Romania was conducted to assess the WTP for COVID-19 
vaccine candidate and found that the acceptable price range 
of the vaccine was between 20 and 200 EUR (equivalent with 
US$ 23.63 and 236,18, respectively, using an August 2020 
exchange rate 1 EUR = US$ 1.18).15 In a recent study in 
Chile, WTP for a COVID-19 vaccine was approximately US 
$184.16 In southeast Asia, the only available data were gener-
ated from a study in Malaysia.17 The study found that the mean 
WTP for a dose of COVID-19 vaccine was US$ 30.66.17 To add 
more information in the literature, we undertook a study in 
Indonesia. This study’s main objective was to determine how 
much money members of the general community would be 
willing to pay for a COVID-19 vaccine when it is available (i.e. 
WTP) and to assess the associated determinants with 
this WTP.
Since there is no available COVID-19 vaccine, 
a hypothetical vaccine approach was adopted as has previously 
used for new vaccines against dengue,9,10,12 Ebola,18–21 
chikungunya,20 Zika,22,23 and COVID-19.15,16 To estimate the 
WTP, the contingent valuation approach was adopted. This 
method has been used to estimate WTP for many hypothetical 
vaccines such as against dengue,11,24,25 Zika,22,23 HIV,26 
rabies27 as well as COVID-1916 since it is able to calculate 
a precise WTP with its confidence interval with relatively 
high statistical power.16,28 With the current escalating pan-
demic and its massive impact on the global economy,29 these 
results will be important in formulating a COVID-19 vaccine 
financing when it is available not only in Indonesia but also in 
other countries in the region.
Methods
A cross-sectional online survey was conducted in the general 
population of Indonesia between March 25 and April 6, 2020. 
The mode of an online survey was chosen due to the difficulty 
in doing a face-to-face study amid the ongoing COVID-19 
outbreak. The target population in this study was the adult 
population who were able to read and understand the national 
language Bahasa Indonesia. Using a simplified snowball sam-
pling technique, sample recruitment was conducted among 
community members in six provinces (Aceh, Bali, DKI 
Jakarta, Jambi, West Sumatra, and Yogyakarta) out of 34 pro-
vinces in the country. Participants were asked about 
a hypothetical vaccine, using an approach applied in previous 
studies.9,10,12,15,16,18–23
Invitations with a link to complete a 10 min long survey, 
hosted by Google Forms, were distributed through the 
WhatsApp communication platform as a direct message. 
Those who were directly invited to participate were also 
requested to pass the invitations to their WhatsApp contacts. 
WhatsApp was chosen since a majority of Indonesians (64%) 
across sociodemographic characteristics use this platform. 
Therefore, it enabled us to reach the general population both 
from high and low socioeconomic status, which is critical for 
WTP studies.
Prior to participating in the survey, a potential participant 
was first shown a webpage that contained brief information 
about the study and the aims of the study, estimated comple-
tion time, the identity of the principal investigators, contact 
details, and collaborating institutions. At the end of the page, 
an informed consent document was provided and individuals 
had to agree by checking a checkbox “Yes” before they could 
proceed to the survey. During the survey, no electronic signa-
tures were required and the IP addresses of participants were 
not collected. To ensure confidentiality, only the principal 
investigators had access to the survey account. The potential 
participants were informed that they could exit the survey at 
any point, but that existing responses would still be recorded. 
At the end of the survey period, the data were extracted from 
the survey host and imported into statistical software for ana-
lysis. The survey was voluntary and no incentive was offered.
A set of questions was developed to assess WTP and to 
collect a range of potential determinants such as sociodemo-
graphic data, monthly income, exposure to COVID-19 infor-
mation, and perceived risk of being infected with SARS-CoV-2. 
Prior to the actual study, the questions were tested in a small 
pilot study and were finalized based on feedback.
The response variable in this study was WTP for a COVID- 
19 vaccine. To evaluate WTP, it was hypothesized that 
a COVID-19 vaccine had been developed and tested in the 
clinical trials in human and showed a 95% efficacy to prevent 
COVID-19 in nonimmune population with a 5% chance to 
produce of a mild adverse effect such as pain on the skin, skin 
rash and fever. No information about dosing was provided. 
A simple dichotomous contingent valuation approach25 was 
used with modification in which no open-ended questions 
were provided. Participants were first asked if they would 
accept a COVID-19 vaccine. If yes, they were asked about 
WTP. The first bid was Indonesian Rupiah (IDR) 500,000 
(equivalent with US$ 30.94 using an April 2020 exchange rate 
of 1 US$ = IDR 16,159.80). Then, the bid was either doubled to 
IDR 1 million (US$ 61.88) with the highest bid was 2.5 million 
(US$ 154.70) or halved to IDR 250.000 (US$ 15.47) (Figure 1). 
The lowest and the highest price provided were US$ 15.47 and 
US$ 154.70, respectively. The possible responses for each bit 
were “yes” or “no.” A participant who refused to pay at the 
lowest bid (i.e. US$ 15.47) was considered not willing to pay. 
The WTP for each participant was defined as the maximum 
amount of money that participants would be willing to pay (i.e. 
the highest bid where the participant responded “yes”).
Some determinants such as sociodemographic characteristics, 
preexisting exposure to COVID-19 information, and perceived 
risk were collected. Sociodemographic characteristics included 
age, gender, educational attainment, occupation, religion, marital 
status, individual monthly income, and whether the participant 
resided in an urban or rural area. Monthly income was grouped 
into: (a) less than IDR 2.5 million (<US$ 154.70); (b) IDR 
2.5–5 million (US$ 154.70–US$ 309.41); (c) IDR 6–10 million 
(US$ 371.29–US$ 618.81); and (d) more than IDR 10 million 
(>US$ 618.81). Perceived risk, defined as the perceived risk of 
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contracting COVID-19 within the next month, was assessed on 
a scale from 0% to 100% as explained previously.30
A linear regression model was used to assess determinants 
associated with WTP as described previously.9,18,23 
Diagnostic assessments were carried out to assess multicolli-
nearity, heteroscedasticity, and residual normality.9,23 The 
Variance Inflation Factor (VIF)31 was used to assess the 
multicollinearity and a VIF lower than 10 and tolerance 
value (1/VIF) of greater than 0.1 were used as a cutoff 
point to indicate that there was no multicollinearity between 
determinants. Heteroscedasticity and residual normality 
assumptions were checked using Glejser test32 and 
Kolmogorov–Smirnov test,33 respectively. A p-value greater 
than 0.05 in the Glejser and Kolmogorov–Smirnov tests 
indicated that the residuals have a constant variance (homo-
scedasticity), and distributed normally. Since the initial 
assessment indicated the WTP response data violated hetero-
scedasticity and normality of residual assumptions, the data 
were then transformed using a natural logarithm func-
tion (ln).
With a log-transformation of the outcome, the WTP data 
were then on a ratio scale, which is widely accepted and used in 
previous vaccine studies.9,18,23,27,34,35 We calculated the 95% 
confidence interval (CI) for each independent variable. For 
a determinant measured in categorical variables, one of the 
categories was designated as the reference category. In the 
initial model, all determinants were included and all determi-
nants with p < .05 in this model were entered the final model.
The mean of the estimated WTP was calculated as described 
previously.9,23 The mean of the estimated WTP was calculated 
as described previously.9,23 The mean of the estimated WTP 
was calculated in US$ as Exp Xβ̂þ σ̂2=2
  �
where the β̂ and σ̂2 
were estimated regression coefficients and the mean squared 
error (MSE) of the regression model, respectively.36,37
Results
During the study period, 1,359 respondents completed the 
survey. Of the total, 91 (6.6%) would reject the vaccine even if 
it was provided freely, and 203 (14.9%) stated that they would 
like to be vaccinated only if the vaccine was provided for free, 
leaving 1,065 (78.3%) participants willing to pay for a vaccine 
and included in the WTP analysis. The characteristics of those 
who were willing to pay for the vaccine are provided in Table 
1. More than half (53.1%) of the participants were aged 
21–30 y old, the majority (68.5%) were females, and more 
than two-third graduated from a university. Almost half 
earned less than US$ 123.76 a month and most of the 
Figure 1. Iterative bidding technique used to determine the WTP for a COVID-19 
vaccine.
Table 1. Demographic characteristics of participants who were willing to pay for 












Junior/senior school graduated 275 (25.8)
Diploma graduated 58 (5.4)
University graduated/post-graduated 732 (68.7)
Occupation
Civil servant 214 (20.1)













Monthly income (Indonesian Rupiah)
< 2.5 million 501 (47.0)
2.5–5 million 321 (30.1)
6–10 million 160 (15.0)







Have heard about COVID-19
No 13 (1.2)
Yes 1052 (98.8)
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respondents (78.4%) lived in cities. Although the vast major-
ity (98.8%) of participants stated that they had heard about 
COVID-19 prior to the study, 35.1% perceived a 0% risk to be 
infected within the next month.
The mean and median WTP was US$ 57.20 (95%CI: US$ 
54.56, US$ 59.85) and US$ 30.94 (95%CI: US$ 30.94, US$ 
30.94), respectively. Among total participants, 78.4% (1065/ 
1359), 55.4% (753/1359), 34.4% (468/1359), and 21.8% (296/ 
1359) of them were willing to pay when the vaccine price US$ 
15.47, US$ 30.94, US$ 61.88, and US$ 123.76, respectively. 
Among participants who were willing to pay, 29.3% (312/ 
1065) were willing to pay only US$ 15.47. This percentage 
decreased to 26.7% (285/1065), 16.1% (172/1065), and 27.7% 
(296/1065) as the price increased to US$ 30.94, US$ 61.88, and 
US$ 123.76, respectively.
Our initial, unadjusted linear regression model indicated 
that working as HCWs, religion, individual monthly income, 
and perceived risk were associated with changes in WTP 
(Table 2). Our final, multivariable model revealed that all of 
those determinants were also associated with changes in 
WTP with monthly income being the strongest determinant 
of WTP change (Table 3). HCWs had a higher WTP of 
approximately US$ 1.62 compared to non-HCW and parti-
cipants who identified themselves as Catholics had higher 
WTP compared to Moslems, approximately US$ 2.08 
(Table 3). Compared to respondents who earned less than 
US$ 154.70, participants who belong to higher income 
groups (US$ 154.70–US$ 309.41; US$ 371.29–US$ 618.82, 
and >US$ 618.81) also had higher WTP, approximately US 
$ 1.84, US$ 2.01, and US$ 2.82, respectively. Participants 
whose perceived risk was more than 60% had higher WTP 
(US$ 1.84) compared to those who believed that they would 
not be infected.
Discussion
It is not clear what the price of the COVID-19 vaccine will be, 
when it becomes available, but since COVID-19 is a pandemic 
that is impacting all countries, the vaccine is likely to receive 
public subsidies. Countries with limited resources will have to 
develop a payment scheme that balances costs and benefits. 
This optimal price will depend on the dynamics of what pro-
portion of the community will accept the vaccine and how 
much they are willing to pay for the vaccine.
Table 2. Initial multivariable linear regression model showing factors associated with the willingness-to-pay for a COVID-19 vaccine in Indonesia (n = 1,065).
Variables
Unstandardized coefficients US-$ estimate
P-valueB
95% CI of B
SE Mean
95% CI
Lower Upper Lower Upper
Intercept 3.670 3.159 4.181 0.260 53.190 51.660 54.720 <0.001
Age group (17–20 y)
21–30 y −0.053 −0.228 0.123 0.089 1.286 −0.244 2.816 0.556
31–40 y −0.129 −0.365 0.107 0.120 1.191 −0.339 2.721 0.282
41–50 y −0.211 −0.516 0.093 0.155 1.097 −0.433 2.627 0.173
≥ 51 y −0.161 −0.483 0.161 0.164 1.154 −0.376 2.683 0.327
Gender (Male)
Female −0.082 −0.187 0.023 0.054 1.249 −0.281 2.778 0.127
Education attainment (Junior/senior high school)
Diploma −0.176 −0.426 0.075 0.128 1.137 −0.393 2.667 0.169
Undergraduate/graduated −0.072 −0.223 0.079 0.077 1.261 −0.269 2.791 0.348
Occupation (Civil servant)
Private sector employee −0.242 −0.395 −0.089 0.078 1.064 −0.465 2.594 0.002
Entrepreneur −0.165 −0.357 0.026 0.097 1.149 −0.381 2.678 0.090
Student 0.012 −0.199 0.224 0.108 1.372 −0.158 2.902 0.909
Retired −0.249 −0.723 0.226 0.242 1.057 −0.473 2.587 0.304
Medical staff (No)
Yes 0.192 0.060 0.324 0.067 1.642 0.112 3.172 0.004
Religion (Islam)
Buddhism −0.032 −0.293 0.229 0.133 1.312 −0.217 2.842 0.808
Christian 0.212 −0.049 0.473 0.133 1.675 0.146 3.205 0.111
Catholic 0.447 0.117 0.777 0.168 2.120 0.590 3.650 0.008
Others 0.393 −0.126 0.913 0.265 2.008 0.478 3.538 0.138
Marital status (Single)
Married 0.098 −0.047 0.242 0.074 1.494 −0.035 3.024 0.184
Monthly income, Indonesian Rupiah (<2.5 millions)
2.5–5 million 0.316 0.179 0.453 0.070 1.859 0.329 3.388 <0.001
6–10 million 0.382 0.206 0.559 0.090 1.986 0.457 3.516 <0.001
>10 million 0.722 0.503 0.940 0.111 2.789 1.259 4.319 <0.001
Urbanicity (Rural)
Urban 0.002 −0.116 0.121 0.060 1.359 −0.171 2.888 0.968
Have heard about COVID-19 (No)
Yes 0.032 −0.401 0.465 0.221 1.399 −0.130 2.929 0.885
Perceived risk to be infected with COVID-19 (0%)
10–20 −0.107 −0.227 0.014 0.062 1.218 −0.311 2.748 0.084
30–40 −0.035 −0.184 0.114 0.076 1.309 −0.221 2.838 0.643
50–60 0.062 −0.078 0.202 0.071 1.443 −0.087 2.972 0.382
> 60 0.299 0.039 0.560 0.133 1.828 0.299 3.358 0.024
MSE 0.608
F-value (P < .001) 4.949
R2 0.110
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Our study demonstrated that a vast majority of 
Indonesian adults responding to our survey were willing to 
obtain and pay for a COVID-19 vaccine and only a small 
fraction of 6.6% (91/1,359) were not willing to be vaccinated. 
However, among those who were willing to be vaccinated, 
16.1% (203/1260) expressed that they were not even willing 
to pay US$ 15.47. This suggests that if the vaccine price will 
be higher than US$ 15.47 (IDR 250,000), one-fifth of the 
population, at least, in studied provinces may not become 
vaccinated. This could lead to problems attaining herd 
immunity. Currently, it is estimated that perhaps 60% of 
individuals need to be immune to attain herd immunity,38 
but with an imperfectly effective vaccine, that would mean 
an even larger proportion of the population would need to 
be vaccinated. With our study results, it is doubtful that herd 
immunity through vaccination could be obtained without 
financial subsidies to vaccination.
Our study found that monthly income is the strongest 
predictor for a positive WTP change, and this relationship 
has been demonstrated previously.10,12,23,39–41 This may reflect 
a direct correlation between WTP and ability to pay, or an 
indirect correlation that those with higher income may have 
a greater understanding of the benefit of vaccination. To be 
more explicit in the relationship between income and WTP, 
knowledge of participants about the COVID-19 vaccine should 
be explored. Although our study did not measure participants’ 
knowledge about COVID-19, the contribution of knowledge 
toward a higher WTP may be reflected by a higher WTP for 
a COVID-19 vaccine among HCWs compared to those who 
were working in non-medical sectors. A previous study also 
found that HCWs are more supportive of a COVID-19 vaccine 
than non-HCWs.42 In an outbreak event, HCWs’ awareness of 
infection control can be a driver in their decision to become 
vaccinated.43,44
Apart from sociodemographic and socioeconomic status, 
knowledge of the disease, attitude toward the disease, and 
attitude toward vaccination are associated with WTP for 
a new vaccine.9–12 In the context of COVID-19, knowledge of 
COVID-19, perception of government performance, and 
COVID-19-related experiences such as being sick with or has 
recovered from COVID-19 were associated with the WTP.16 In 
this present study, those factors were not adequately investi-
gated. Nevertheless, our study found that perceived risk for 
COVID-19 was associated with WTP only when perceived risk 
was higher than 60% (i.e. the individual believed that there was 
a > 60% chance to be infected within the next month). This 
factor should receive more attention since this is the only 
modifiable determinant for WTP in this study. Previous studies 
have found that perceived risk or perceived susceptibility is 
associated with positive vaccination support13,45 and those 
with higher perceived risk had greater acceptance for 
COVID-19 vaccine.42 Well-designed programs to increase per-
ceived risk for COVID-19 might be also necessary to increase 
a positive attitude for vaccination because this factor is the 
strongest determinant for acceptance46 and WTP for a new 
vaccine.9 It is also important to consider other determinants of 
vaccine uptake – ease of access, awareness of the vaccine, and 
nudges can all increase uptake.47
Some limitations of this study need to be discussed. Although 
this study used the WhatsApp planform to reach those with low 
income and in the rural area, the generalizability of the results 
from this study should be done with caution due to sampling 
bias. In January 2020, internet penetration in Indonesia was 
approximately 64%,48 but internet infrastructure differences 
across the country (which are better in cities than rural areas) 
indicate the possibility of sampling bias.49,50 Based on Statistics 
Indonesia, in 2019, the national average of individual monthly 
income in the country was approximately US$ 304.75.51 In the 
Table 3. Final multivariable linear regression model showing factors associated with the willingness-to-pay for a COVID-19 vaccine in Indonesia (n = 1,065).
Variables
Unstandardized coefficients US-$ estimate
P-valueB
95% CI of B
SE Mean
95% CI
Lower Upper Lower Upper
Intercept 3.524 3.349 3.700 0.089 45.963 44.434 47.491 <0.001
Occupation (Civil servant)
Private sector employee −0.229 −0.371 −0.087 0.072 1.077 −0.451 2.606 0.002
Entrepreneur −0.135 −0.315 0.045 0.092 1.184 −0.345 2.712 0.142
Student 0.069 −0.107 0.244 0.089 1.451 −0.078 2.979 0.444
Retired −0.185 −0.640 0.271 0.232 1.126 −0.402 2.655 0.427
Medical staff (No)
Yes 0.183 0.054 0.312 0.066 1.627 0.098 3.155 0.005
Religion (Islam)
Buddhism −0.031 −0.287 0.225 0.131 1.313 −0.215 2.842 0.813
Cristian 0.198 −0.061 0.456 0.132 1.651 0.122 3.179 0.134
Catholic 0.432 0.104 0.760 0.167 2.087 0.558 3.615 0.010
Others 0.397 −0.120 0.915 0.264 2.015 0.487 3.544 0.132
Monthly income, Indonesian Rupiah (<2.5 millions)
2.5–5 million 0.311 0.176 0.445 0.069 1.848 0.320 3.377 <0.001
6–10 million 0.397 0.226 0.568 0.087 2.015 0.486 3.543 <0.001
>10 million 0.734 0.527 0.941 0.105 2.822 1.293 4.350 <0.001
Perceived risk to be infected with COVID-19 (0)
10–20 −0.102 −0.221 0.018 0.061 1.224 −0.305 2.752 0.096
30–40 −0.028 −0.174 0.118 0.075 1.317 −0.211 2.846 0.706
50–60 0.054 −0.083 0.191 0.070 1.429 −0.099 2.958 0.442
> 60 0.306 0.047 0.566 0.132 1.840 0.311 3.368 0.021
MSE 0.607
F-value (P < .001) 4.574
R2 0.103
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present study, 47% of the respondents had monthly income less 
than US$ 154.70, and 30.1% earned between US$ 154.70–US$ 
309.41 each month suggesting the income of respondent study is 
relatively lower compared to the estimated national income. This 
could have an implication that the WTP found in this study 
might be lower compared to the actual WTP of the general 
population in Indonesia. Nevertheless, most of the study parti-
cipants were from urban areas resulting in a low inclusion rate of 
those with low educational attainment. In Indonesia, rural dwell-
ers generally have less wealth and lower educational attainment. 
Although we did not observe a significant association between 
urbanicity or education on WTP, as in previous studies,9,21 
this sampling bias may have shifted the observed WTP than 
in the actual general population. Additionally, in this study, 
we gave respondents information about a 95% effective vac-
cine. But the vaccine may prove to have lower effectiveness, 
which itself could impact acceptance52 and WTP for the 
vaccine.
Conclusion
When a very effective COVID-19 vaccine is available, more than 
70% of community members in Indonesia likely will be willing to 
pay for the vaccine with the mean WTP approximately US$ 57. 
Having higher individual monthly income and higher perceived 
risk of being infected with COVID-19 are associated with WTP. 
One important modifiable determinant associated with WTP is 
the perceived risk of contracting COVID-19, which could be 
targeted in health promotions. Health promotions could be 
combined with vaccine price subsidies in order to attain an 
adequately high vaccination coverage.
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